The Claim
Adults with obesity or overweight without diabetes who continued tirzepatide for 88 weeks achieved a mean total weight reduction of 25.3% from baseline, compared to 9.9% in those who switched to placebo after the 36-week open-label lead-in.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In a study lasting 88 weeks, adults with obesity or overweight who stayed on tirzepatide lost on average 25.3% of their starting weight, while those who switched to a placebo lost only 9.9%.
See the scientific wording
Over the entire 88-week study period (36-week open-label lead-in plus 52-week double-blind period), adults with obesity or overweight without diabetes who continued tirzepatide achieved a mean total weight reduction of 25.3% from baseline, compared to 9.9% in those who switched to placebo after the lead-in period.
Tirzepatide works by activating two types of hormone receptors in the brain and body. This action reduces appetite, leading to less calorie intake, and improves how the body processes sugar and burns energy. Together, these effects produce and maintain significant weight loss over time.
What the research says
1 studyThe study found exactly what the claim says: people who stayed on tirzepatide lost about 25% of their starting weight on average, while those who stopped lost only about 10%.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.